Should you buy CSL and ResMed shares in January?

Let's see what one leading broker is saying about these blue chips.

| More on:
Six smiling health workers pose for a selfie.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) and ResMed Inc (ASX: RMD) shares are popular blue chip options for investors.

But are they in the buy zone right now?

Let's take a look at what one leading broker is saying about these high-quality companies in January.

Are CSL shares a buy?

According to a note out of Goldman Sachs, its analysts think that investors should snap up this biotherapeutics giant's shares before they rally.

After several years of underperformance, the broker believes that the company is destined to deliver strong earnings growth through to FY 2028. It said:

Our Buy thesis is driven by (1) Double digit IG growth (GSe: +12.6% FY23-FY28E CAGR) underpinned by low penetration (including CIDP) and ~100bps YoY market share gains. Our channel checks indicate CSL's competitive advantages are intact, with the expansion in fractionation capacity set to enhance CSL's superior cost profile and supply reliability, (2) Strong Gross Margin (GM%) recovery with Behring plasma collection costs per liter set to meaningfully decline (-14.6% FY26E vs FY24), and (3) Rebound in Seqirus growth from depressed US influenza vaccination rates.

Goldman has a buy rating and $325.40 price target on CSL's shares. This implies potential upside of 19% for investors over the next 12 months.

What about ResMed shares?

Goldman also thinks that sleep disorder treatment company ResMed would be a great option for investors right now.

It is bullish on the blue chip due to its huge market opportunity, potential market share gains, and expanding margins. It said:

Our Buy thesis is underpinned by (1) Robust Continuous Airway Pressure Therapy (CPAP) patient growth assisted by growing awareness on Obstructive Sleep Apnea (OSA), (2) Market share gains, particularly in OSA masks and (3) Operating margin expansion driven by product mix and solid cost management.

Goldman also points out that it believes weight loss wonder drugs are not to be feared. It adds:

We believe GLP-1 drugs to treat OSA will co-exist with CPAP therapy based on the published clinical data and payor policies to date. Engagement on RMD's patient app (myAir) indicates ongoing momentum in therapy compliance, noting the potential of the rate of OSA diagnosis to step up from Zepbound's (GLP-1 drug from LLY) Medicare's coverage.

The broker has a buy rating and $48.90 price target on ResMed's shares. Based on its current share price of $38.84, this implies potential upside of approximately 26% for investors over the next 12 months.

Should you invest $1,000 in CSL right now?

Before you buy CSL shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and CSL wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor James Mickleboro has positions in CSL and ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Goldman Sachs Group, and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Blue Chip Shares

A bland looking man in a brown suit opens his jacket to reveal a red and gold superhero dollar symbol on his chest.
Blue Chip Shares

If I were building a portfolio from scratch, I'd buy these 3 ASX 200 shares today

These quality shares could be great picks for investors building a portfolio.

Read more »

A bland looking man in a brown suit opens his jacket to reveal a red and gold superhero dollar symbol on his chest.
Blue Chip Shares

Why these super blue chip ASX 200 shares could deliver big returns

Analysts think these shares are top picks for investors looking for blue chips to buy.

Read more »

A man with a wide, eager smile on his face holds up three fingers.
Blue Chip Shares

3 ASX blue-chip shares I'd buy with $3,000 right now

Here’s why these businesses are appealing opportunities to me.

Read more »

Three happy office workers cheer as they read about good financial news on a laptop.
Blue Chip Shares

3 of the best ASX 200 shares to buy now with $5,000

Investors with money to invest might want to check out these shares that analysts rate as buys.

Read more »

Beautiful holiday photo showing two deck chairs close-up with people sitting in them enjoying the bright blue ocean and island view while sipping champagne and enjoying the good life thanks to Pilbara Minerals share price gains in recent times
Blue Chip Shares

3 ASX 200 blue chips to compound your way to riches

Analysts think these blue chips would be top picks for buy and hold investors.

Read more »

A businessman hugs his computer and smiles.
Blue Chip Shares

3 excellent ASX shares I would buy and hold for the next 10 years

Analysts think these quality companies could be in the buy zone right now.

Read more »

A group of people in suits watch as a man puts his hand up to take the opportunity.
Blue Chip Shares

The ultimate blue chip portfolio: 3 ASX 200 stocks to anchor your investments

Starting your investment journey? Here are three stocks that Goldman Sachs rates very highly.

Read more »

Happy shareholders clap and smile as they listen to a company earnings report.
Blue Chip Shares

3 quality ASX stocks that could lead the next market rebound

These stocks are highly rated by analysts for a reason. Here's what you need to know.

Read more »